2020
Adherence to study drug in a stroke prevention trial"?>
Kiran A, Viscoli CM, Furie KL, Gorman M, Kernan WN. Adherence to study drug in a stroke prevention trial"?>. Journal Of Stroke And Cerebrovascular Diseases 2020, 29: 105048. PMID: 32912514, PMCID: PMC7487071, DOI: 10.1016/j.jstrokecerebrovasdis.2020.105048.Peer-Reviewed Original ResearchConceptsRate of discontinuationStudy drugDrug holidayTreatment groupsActive study drugAdverse effectsInsulin Resistance InterventionPremature drug discontinuationRecent ischemic strokeStroke Prevention TrialDouble-blind trialTransient ischemic attackClinical trial researchPhases of adherenceDrug discontinuationIschemic attackStroke preventionDiscontinuation ratesIschemic strokeActive therapyMedical therapyPatient adherencePrevention trialsStroke trialsPharmacodynamic effects
2011
Boosting enrolment in clinical trials: validation of a regional network model
Kernan W, Viscoli C, Brass L, Amatangelo M, Birch A, Clark W, Conwit R, Furie K, Gorman M, Pesapane B, Kleindorfer D, Lovejoy A, Osborne J, Silliman S, Zweifler R, Horwitz R. Boosting enrolment in clinical trials: validation of a regional network model. Clinical Trials 2011, 8: 645-653. PMID: 21824978, PMCID: PMC3852692, DOI: 10.1177/1740774511414925.Peer-Reviewed Original ResearchConceptsClinical trialsTransient ischemic attackNames of patientsEligible patientsIschemic attackStroke preventionDrug adherenceStroke therapyActive surveillanceAverage monthly rateHome visitsPatientsHospitalTrial researchParticipant costsOutreach NetworkMultiple hospitalsTrialsStudy intervalNational InstituteEnrollmentMonthly rateStrokeParticipantsReproducible method
2009
Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs)
Kernan WN, Viscoli CM, DeMarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs). Neurology 2009, 72: 1345-1351. PMID: 19365056, PMCID: PMC2677492, DOI: 10.1212/wnl.0b013e3181a0fda3.Peer-Reviewed Original ResearchConceptsOutreach NetworkCentral coordinating centerInsulin Resistance InterventionSecondary stroke preventionNames of patientsResults of surveillanceStroke preventionMore patientsStroke siteConnecticut hospitalsTrial participantsHome visitsPatientsResistance InterventionPersonal physicianElectronic admissionRandomization ratesCoordinating CenterMore rapid completionMonthsHigher enrollment ratesHospitalRecruitment strategiesTrialsParticipants
2005
Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST)
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal Of Obstetrics And Gynecology 2005, 192: 387-393. PMID: 15695976, DOI: 10.1016/j.ajog.2004.08.017.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationEstrogen therapyCognitive declineNormal Mini-Mental State ExaminationDouble-blind trialSecondary stroke preventionTransient ischemic attackIschemic attackPostmenopausal womenStroke preventionRecent strokeStroke trialsCerebrovascular diseaseWomen's EstrogenEstradiol-17betaState ExaminationCognitive measuresEstrogenWomenNormal functionDomain measuresLess declineTherapyStrokeRisk
2002
Insulin resistance and risk for stroke
Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002, 59: 809-815. PMID: 12349850, DOI: 10.1212/wnl.59.6.809.Peer-Reviewed Original ResearchConceptsInsulin resistanceRisk factorsProspective observational cohort studyType 2 diabetes mellitusInsulin-mediated glucose uptakeObservational cohort studyPrevalent risk factorsImportant risk factorType 2 diabetesCase-control studyPertinent English-language publicationsEnglish-language publicationsCardinal defectsPhysical deconditioningStroke preventionCohort studyMost patientsDiabetes mellitusPathophysiologic defectsNondiabetic individualsVascular diseasePeripheral tissuesElderly personsStrokeDefective glycogen synthesis